Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search
		×
			Vaccines site
			Vaccines site
				All CDC
				Submit
			For a full list of topics:A-Z Index
			Advanced Search
		Advanced Search


Advisory Committee on Immunization Practices (ACIP)








Grading of Recommendations, Assessment, Development, and Evaluation (GRADE): Lyophilized CVD 103-HgR Vaccine Among Children and Adolescents Aged 2–17 Years						Print
																Related Pages
										Overview
A Grading of Recommendations, Assessment, Development and Evaluation (GRADE) review of the evidence for benefits and harms for use of lyophilized CVD 103-HgR vaccine (CVD 103-HgR) among children and adolescents aged 2–17 years was presented to the Advisory Committee for Immunization Practices (ACIP) on January 12, 2022. GRADE evidence type indicates the certainty of estimates from the available body of evidence, ranging from type 1 (high certainty) to type 4 (very low certainty).1 The policy question was “Should ACIP recommend lyophilized CVD 103-HgR vaccine for children and adolescents aged 2–17 years traveling to an area with active cholera transmission?” (Table 1).
The potential benefits pre-specified by the ACIP Cholera Vaccine Work Group were moderate to severe cholera diarrhea (critical) and cholera diarrhea of any severity (critical). The two pre-specified harms were serious adverse events (SAEs) (critical) and non-serious adverse events (important) (Tables 1 and 2). The work group conducted a systematic review of evidence on the benefits and harms of CVD 103-HgR among children and adolescents aged 2–17 years old. Studies identified were assessed using a modified GRADE approach.1
Regarding benefits, no studies of CVD 103-HgR in children and adolescents aged 2–17 years directly assessed vaccine efficacy or effectiveness against cholera diarrhea. The available data from randomized control trials (RCTs) demonstrated that, compared with placebo, vaccination was associated with a higher risk of serum vibriocidal antibody (SVA) seroconversion (pooled relative risk [RR]: 65.99, 95% CI: 9.43–461.69; pooled absolute risk [AR]: 97,000 more per 100,000, 95% CI: 12,582 more to 100,000 more). The evidence certainty was downgraded for serious imprecision, and the final level of certainty was type 2 (moderate) for both benefits.
Regarding harms, the available data from RCTs demonstrated the vaccine and placebo arms had a similar risk of serious adverse events (pooled RR: 0.16, 95% CI 0.01–2.53; pooled AR: 1,120 fewer per 100,000, 95% CI: 1,320 fewer to 2,040 more); no serious adverse events were judged to be related to the vaccine among 468 recipients aged 2–17 years within 6 months of vaccination. The risk of non-serious adverse events was similar between the vaccine and placebo groups (pooled RR: 1.09, 95% CI 0.86–1.38; pooled AR: 4,560 more per 100,000, 95% CI: 7,093 fewer to 19,253 more). For both harms, the evidence certainty was downgraded for very serious imprecision, and the final certainty was type 3 (low).
Introduction
In December 2020, the U.S. Food and Drug Administration (FDA) extended the approved usage of Vaxchora to include children and adolescents aged 2 through 17 years.2 As part of the process used by the Advisory Committee for Immunization Practices (ACIP), a systematic review and Grading of Recommendations, Assessment, Development and Evaluation (GRADE) assessment of the evidence for CVD 103-HgR among children and adolescents aged 2–17 years was conducted and presented to ACIP on January 12, 2022.1
Methods
We conducted systematic reviews of evidence on the benefits and harms of CVD 103HgR in children and adolescents aged 2–17 years using a modified GRADE approach.1 The policy question was “should CVD 103-HgR be recommended for children and adolescents aged 2–17 years traveling to an area with active cholera transmission?” (Table 1).
During Work Group calls, members were asked to pre-specify and rate the importance of relevant patient-important outcomes (including benefits and harms) before the GRADE assessment. No conflicts of interest were reported by CDC and ACIP Cholera Vaccine Work Group members involved in the GRADE analysis. The pre-specified benefits (importance) were moderate to severe cholera diarrhea (critical) and cholera diarrhea of any severity (critical). The two pre-specified harms were serious adverse events (SAEs) (critical) and non-serious adverse events (important) (Table 2). Indirect effects of vaccination were not considered as part of GRADE.
We identified studies written in English through PubMed, Embase, and Cochrane Library. Records of relevant Phase I, II, III, or IV clinical trials were included if they 1) provided data on the current formulation and dose of CVD 103-HgR, 2) involved human subjects aged 2–17 years, 3) reported primary data relevant to the efficacy and safety outcomes, and 4) were conducted in cholera non-endemic settings. In addition, unpublished and other relevant data were obtained by hand-searching reference lists and by consulting with vaccine manufacturers and subject matter experts. Characteristics of all included studies are shown in Appendix 1,3–5 and evidence retrieval methods are shown in Appendix 2.
The evidence certainty assessment addressed risk of bias, inconsistency, indirectness, imprecision, and other characteristics. The GRADE assessment across the body of evidence for each outcome was presented in an evidence profile; the evidence certainty of Type 1, 2, 3, or 4 corresponds to high, moderate, low, or very low certainty, respectively.
Results
The results of the GRADE assessments were presented to ACIP on January 12, 2022. Overall, 571 records were identified and screened; 557 records were excluded based on the title because they were published before the current formulation was available (n=404), they did not report a cholera vaccine trial (n=105), or they reported on a different cholera vaccine or non-endemic setting (n=48). Of the 14 articles deemed eligible for full-text review, 11 were excluded (10 for being conducted in adults, and 1 for being a different formulation). The remaining 3 articles were included in the evidence synthesis and GRADE assessment (Appendix 1). These three records summarized a phase IV, randomized, double-blind placebo-controlled trial among children and adolescents aged 2–17 years.3–5 When data relevant to the PICO outcomes were not available in these records, additional data were obtained from the study sponsor.6
No studies of CVD 103-HgR in children and adolescents aged 2–17 years directly assessed vaccine efficacy or effectiveness. Assessment of both benefits (moderate to severe cholera diarrhea and cholera diarrhea of any severity) was based on immunobridging to adults, in whom efficacy has been demonstrated.7 Three studies in children and adolescents aged 2–17 years reported data on immunogenicity;3–5 two of these reported on serum vibriocidal antibody (SVA) seroconversion (defined as ≥4-fold rise in serum vibriocidal antibody titer) on day 11, the primary immunologic parameter used to assess both benefits (Table 3a).3,4 Seroconversion on day 11 was more likely among CVD 103-HgR recipients (98.5%) than placebo recipients (1.5%) (pooled RR: 65.99, 95% CI: 9.43–461.69; pooled AR: 97,000 more per 100,000, 95% CI: 12,582 more to 100,000 more) (Table 3a, Table 4).3,4,6
Two studies reported data on serious adverse events through day 181 after vaccination (Table 3b).3,4 Serious adverse events occurred among 1/468 (0.2%) vaccine recipients and 1/75 (1.3%) placebo recipients  (pooled RR: 0.16, 95% CI 0.01–2.53; pooled AR: 1,120 fewer per 100,000, 95% CI: 1,320 fewer to 2,040 more).3,4,6 No serious adverse events were determined to be related to vaccination (Table 3b, Table 4).3,4,6
The frequency of any solicited adverse event within 7 days was used to assess the outcome non-serious adverse events, with data available from two studies.3,4,6 Any solicited adverse event within 7 days after vaccination was reported by 258/468 (55.1%) vaccine recipients and 38/75 (50.7%) placebo recipients (pooled RR: 1.09, 95% CI: 0.86 to 1.38; pooled AR: 4,560 more per 100,000, 95% CI: 7,093 fewer to 19,253 more) (Table 3c, Table 4).3,4,6 Solicited adverse events more commonly reported by vaccine than placebo recipients included tiredness (35.7% vs. 30.7%; mostly mild), headache (27.4% vs. 25.3%, mostly mild), abdominal pain (27.8% vs. 18.7%; mostly mild) and lack of appetite (21.4% vs. 14.7%; mostly mild).3,4,8
GRADE Summary
For all outcomes, the initial evidence level was type 1 (high) because all available data were from randomized control trials. For moderate to severe cholera diarrhea and cholera diarrhea of any severity, CVD 103-HgR effectively induces SVA seroconversion, an imperfect correlate of protection against cholera. The evidence certainty was downgraded for serious indirectness because efficacy was inferred from immunobridging, and the final evidence certainty was type 2 (moderate). For serious adverse events, none were judged to be related to the vaccine; the evidence certainty was downgraded for very serious imprecision, and the final evidence certainty was type 3 (low). The frequency of non-serious adverse events was not meaningfully different among CVD 103-HgR versus placebo recipients; the evidence certainty was downgraded for very serious imprecision, and the final evidence certainty was type 3 (low) (Table 5).
References
Ahmed F. U.S. Advisory Committee on Immunization Practices (ACIP) Handbook for Developing Evidence-based Recommendations, Version 1.2. Atlanta GA: U.S. Department of Health and Human Services, CDC; 2013. Accessed June 14, 2022. www.cdc.gov/vaccines/acip/recs/grade/downloads/handbook.pdf
U.S. Food and Drug Administration. Supplement Approval. Silver Spring, MD. U.S. Department of Health and Human Services, FDA, 2020. Accessed June 14, 2022. https://www.fda.gov/media/144754/download
McCarty JM, Cassie D, Bedell L, Lock MD, Bennett S. Safety and Immunogenicity of Live Oral Cholera Vaccine CVD 103-HgR in Children Aged 2–5 Years in the United States. Am J Trop Med Hyg. 2020;104(3):861–5.
McCarty JM, Gierman EC, Bedell L, Lock MD, Bennett S. Safety and immunogenicity of live oral cholera vaccine CVD 103-HgR in children and adolescents aged 6─17 years. Am J Trop Med Hyg. 2020;102(1):48–57.
McCarty JM, Cassie D, Bedell L, Lock MD, Bennett S. Long-term immunogenicity of live oral cholera vaccine CVD 103-HgR in adolescents aged 12─17 years in the United States. Am J Trop Med Hyg. 2021;104(5):1758–60.
McCarty J (ed). Vaxchora in Children and Adolescents. Advisory Committee on Immunization Practices February 24–25, 2021 Meeting. Atlanta, GA: U.S. Department of Health and Human Services, CDC; 2021. www.cdc.gov/vaccines/acip/meetings/downloads/slides-2021-02/24-25/03-Cholera-McCarty.pdf
Chen WH, Cohen MB, Kirkpatrick BD, et al. Single-dose live oral cholera vaccine CVD 103-HgR protects against human experimental infection with *Vibrio cholerae* O1 El Tor. Clin Infect Dis. 2016;62(11):1329–35.
U.S. Food and Drug Administration. Package Insert – VAXCHORA. Silver Spring, MD. U.S. Department of Health and Human Services, FDA, 2020. Accessed June 14, 2022. https://www.fda.gov/media/128415/downloadTable 1: Policy Question and PICO
Table 1: Policy Question and PICO
Policy question:
Should ACIP recommend lyophilized CVD 103-HgR vaccine for children and adolescents aged 2–17 years traveling to an area with active cholera transmission?Population
Children and adolescents aged 2–17 years traveling to an area with active cholera transmissionIntervention
Lyophilized CVD 103-HgR (single-dose, oral, live-attenuated bacterial vaccine*)Comparison
No cholera vaccineOutcomes
Cholera diarrhea, moderate to severe
Cholera diarrhea, any severity
Serious adverse events
Non-serious adverse events*4×108–2×109 colony forming units with buffer (50 ml if 2–5 years; 100 ml if 6–17 years)Table 2: Outcomes and Rankings
Table 2: Outcomes and Rankings
Outcome
Importance
Included in evidence profileCholera diarrhea, moderate or severe
Critical
YesCholera diarrhea, any severity
Critical
YesSerious adverse events
Critical
YesNon-serious adverse events
Important
Yes
*Three options: 1. Critical; 2. Important but not critical; 3. Not important for decision makingTable 3a: Summary of studies relevant to prevention of moderate to severe cholera diarrhea and cholera diarrhea of any severity (indirect evidence assessed using immunobridginga)
Table 3a: Summary of studies relevant to prevention of moderate to severe cholera diarrhea and cholera diarrhea of any severity (indirect evidence assessed using immunobridging)
Authors last name, pub year
Age or other characteristic of importance
n
vaccine
n
comparator
Outcome measure
(confidence interval)
Study limitations (Risk of Bias)Seroconversion, day 11b,cMcCarty, 20204,6
Children and adolescents aged 6–17 years; phase IV clinical trial
292/296 (98.6%)
1/47 (2.1%)
RR: 46.4 (95% CI: 6.7–322.3)
Not seriousMcCarty, 20203,6
Children aged 2–5 years; phase IV clinical trial
101/103 (98.0%)
0/20 (0%)
RR 41.0 (95% CI: 2.6–634.1)
Not seriousGeometric mean titers (GMT) against classical Inaba *Vibrio cholerae*, day 11McCarty, 20204
Children and adolescents aged 6–17 years; phase IV clinical trial
296
47
Vaccine: 8,531
(95% CI: 7,270–10,009)
Placebo: 41
(95% CI: 29–58)
Not seriousMcCarty, 20203
Children aged 2–5 years; phase IV clinical trial
103
20
Vaccine: 4,852
(95% CI: 3,445–6,832)
Placebo: 28
(95% CI: 20–39)
Not seriousGMT mean fold increase, day 11McCarty, 20204
Children and adolescents aged 6–17 years; phase IV clinical trial
296
47
Vaccine: 268
(95% CI: 229–315)
Placebo 1
(95% CI: 1–1)
Not seriousMcCarty, 20203
Children aged 2–5 years; phase IV clinical trial
103
20
Vaccine: 182
(95% CI: 131–252)
Placebo: 1
(95% CI: 1–1)
Not seriousSeroconversion, day 29bMcCarty, 20214
Children and adolescents aged 6–17 years; phase IV clinical trial
293/296 (99.0%)
2/47 (4.3%)
RR: 23.3 (95% CI: 6.0–90.3)
Not seriousGMT against classical Inaba *Vibrio cholerae*, day 29McCarty, 20203
Adolescents aged 12–17 years; phase IV clinical trial
156
23
Vaccine: 2,749
(95% CI: 2,311–3,270)
Placebo:  43
(95% CI: 27–67)
Not seriousMcCarty, 20203
Children and adolescents aged 6–11 years; phase IV clinical trial
138
23
Vaccine: 1,952
(95% CI: 1,554–2,452)
Placebo: 40
(95% CI: 22–72)
Not seriousMcCarty, 20203
Children aged 2–5 years; phase IV clinical trial
98
18
Vaccine: 1,014
(95% CI: 741–1,387)
Placebo: 27
(95% CI: 21–36)
Not seriousGMT mean fold increase, day 29McCarty, 20203
Adolescents aged 12–17 years; phase IV clinical trial
156
23
Vaccine: 85
(95% CI: 72–102)
Placebo: 1
(95% CI: 1–1)
Not seriousMcCarty, 20203
Children and adolescents aged 6–11 years; phase IV clinical trial
138
23
Vaccine: 62
(95% CI:49–78)
Placebo: 1
(95% CI: 1–2)
Not seriousMcCarty, 20203
Children aged 2–5 years; phase IV clinical trial
98
18
Vaccine: 38
(95% CI: 28–51)
Placebo: 1
(95% CI: 1–1)
Not seriousSeroconversion, day 91bMcCarty, 20215
Adolescents aged 12–17 years; phase IV clinical trial
64/72 (79.6%)
0/23 (0%)
RR: 42.4 (95% CI: 2.7–659.5)
Not seriousGMT against classical Inaba *Vibrio cholerae*, day 91McCarty, 20215
Adolescents aged 12–17 years; phase IV clinical trial
72
23
Vaccine: 391.7
(95% CI: 293.9–522.1)
Placebo: 42.5
(95% CI: 28.7–62.9)
Not seriousGMT mean fold increase, day 91McCarty, 20215
Adolescents aged 12–17 years; phase IV clinical trial
72
23
Vaccine: 12.1
(95% CI: 9.3–15.8)
Placebo: 1.0
(95% CI: 0.7–1.3)
Not seriousSeroconversion day 181bMcCarty, 20215
Adolescents aged 12–17 years; phase IV clinical trial
59/71 (83.1%)
0/21 (0%)
RR: 36.4 (95% CI: 2.3–564.4)
Not seriousGMT against classical Inaba *Vibrio cholerae*, day 181McCarty, 20215
Adolescents aged 12–17 years; phase IV clinical trial
71
21
Vaccine: 223.0
(95% CI: 166.5–298.6)
Placebo: 38.7
(95% CI: 25.8–58.0)
Not seriousGMT mean fold increase, day 181McCarty, 20215
Adolescents aged 12–17 years; phase IV clinical trial
71
21
Vaccine: 6.9
(95% CI: 5.4–8.9)
Placebo: 0.9
(95% CI: 0.8–1.1)
Not serious
aIn an oral challenge study of adults 18–45 years old, the correlation coefficient between cumulative diarrhea (L) and fold-increase in SVA was -0.75 at 10 days and -0.69 at 3 months.7b≥4-fold rise in serum vibriocidal antibody levelcPrimary outcome used for GRADETable 3b: Summary of studies reporting serious adverse eventsa
Table 3b: Summary of studies reporting serious adverse events
Authors last name, pub year
Age or other important characteristics
n/N vaccine
CVD 103-HgR b
n/N comparison b
Comparator
RR (95% CI)
Study limitations (Risk of Bias)McCarty, 20204
Children and adolescents aged 6–17 years; phase IV clinical trial
1/303 (0.33%)c
0/48 (0%)
Placebo
0.48 (0.02–11.7)
Not seriousMcCarty, 20203
Children aged 2–5 years; phase IV clinical trial
0/123 (0%)
1/103 (0.97%)d
Placebo
0.28 (0.01–6.8)
Not serious
aThrough day 181. The clinical trials defined serious adverse events as an adverse event meeting one of the following criteria: resulted in death, was life-threatening, required hospitalization or the prolongation of an existing hospitalization, resulted in a persistent or significant disability or incapacity, resulted in a congenital anomaly or birth defect, required medical or surgical intervention to prevent impairment or damage, other serious important medical event.
bAdditional unpublished data obtained from the manufacturer’s February 2021 presentation to ACIP. Overall, among children and adolescents aged 2–17 years, 1/468 (0.2%) vaccine recipients and 1/75 (1.3%) placebo recipients reported SAEs within 6 months post-vaccination.6
cRight leg fracture deemed unrelated to the vaccine by the sponsor.
dPneumonia and asthma requiring hospitalization.Table 3c: Summary of studies reporting non-serious adverse events
Table 3c: Summary of studies reporting non-serious adverse events
Authors last name, pub year
Age or other important characteristics
n/N vaccine
CVD 103-HgR
n/N comparison
Comparator
RR (95% CI)
Study limitations (Risk of Bias)Any solicited adverse event, day 1–8aMcCarty, 20204
Children and adolescents aged 6–17 years; phase IV clinical trial
199/322 (61.8%)
29/49 (59.2%)
Placebo
1.04 (0.82–1.34)
Not seriousMcCarty, 20203
Children aged 2–5 years; phase IV clinical trial
59/146 (40.4%)b
9/26 (34.6%)
Placebo
1.17 (0.66–2.05)
Not seriousUnsolicited adverse events through day 29McCarty, 20204
Children and adolescents aged 6–17 years; phase IV clinical trial
79/322 (24.5%)
16/49 (32.7%)
Placebo
0.60 (0.38–0.95)
Not seriousMcCarty, 20203
Children aged 2–5 years; phase IV clinical trial
38/146 (26.0%)
6/26 (23.1%)
Placebo
1.13 (0.53–2.40)
Not serious
aIncludes tiredness, headache, abdominal pain, lack of appetite, nausea, vomiting, fever, and diarrhea. Frequencies of individual symptoms did not differ between vaccine and placebo groups, except among 2─5-year-olds: vomiting was significantly more frequent in the placebo group.
bIncludes one case of potentially life-threatening fever T>40oCTable 4: GRADE Summary of Findings
Table 4: GRADE Summary of Findings
Certainty assessment
No of patients
Effect
Certainty
ImportanceNo of studies
Study design
Risk of bias
Inconsistency
Indirectness
Imprecision
Other considerations
Vaccinated
Unvaccinated
Relative
(95% CI)
Absolute
(95% CI)Cholera diarrhea, moderate or severe (assessed with: serum vibriocidal antibody seroconversion, day 11)2
randomized trials
not seriousa
not serious
seriousb,c
not serious
none
393/399 (98.5%) d
1/67 (1.5%)
**RR 65.99**
(9.43 to 461.69)
**97,000 more per 100,000**
(from 12,582 more to 100,000 more)
Moderate (type 2)
CRITICALCholera diarrhea, any severity (assessed with: serum vibriocidal antibody seroconversion, day 11)2
randomized trials
not seriousa
not serious
seriousb,c
not serious
none
393/399 (98.5%) d
1/67 (1.5%)
**RR 65.99**
(9.43 to 461.69)
**97,000 more per 100,000**
(from 12,582 more to 100,000 more)
Moderate (type 2)
CRITICALSerious adverse events (follow-up: mean 6 months)2
randomized trials
not seriouse
not seriousf
not seriousc
very seriousg
none
1/468 (0.2%)
1/75 (1.3%)
**RR 0.16**
(0.01 to 2.53)
**1,120 fewer per 100,000**
(from 1,320 fewer to 2,040 more)
Low (type 3)
CRITICALNon-serious adverse events (solicited) (follow-up: range 1 days to 8 days)2
randomized trials
not serioush
not seriousi
not seriousc
very seriousj
none
258/468 (55.1%)
38/75 (50.7%)
**RR 1.09**
(0.86 to 1.38)
**4,560 more per 100,000**
(from 7,093 fewer to 19,253 more)
Low (type 3)
IMPORTANT
**CI:** confidence interval; **RR:** risk ratio
Loss to follow-up for SVA at day 11: 2–5-year cohort (CVD 103 HgR: 47/150 (32%); Placebo: 6/26 (24%)), 6–11-year cohort (CVD 103-HgR 25/321 (8%); Placebo: 6/53 (11%)).
Serious concern for indirectness because efficacy is inferred from immunobridging. SVA seroconversion is an indirect correlate of protection with biologic plausibility. Dichotomous definition of seroconversion (≥4-fold rise in titer) is different than fold-increases in SVA. In an adult challenge study (Chen, 2016), the correlation coefficient between cumulative diarrhea (L) and fold-increase in serum vibriocidal antibodies was -0.75 at day 10 and -0.69 at 3 months.
The RCTs enrolled healthy children and adolescents aged 2─17 years and my not represent all children and adolescents in this age group, such as those with immunocompromising conditions.
In the double-blind, placebo-controlled phase IV study, seroconversion (≥4-fold rise in serum vibriocidal antibody titer) on day 11 occurred among 292/296 (98.6% [98.3% CI: 95.9─99.6%]) CVD 103-HgR recipients aged 6─17 years and among 101/103 (98.1% [98.3% CI: 91.5─99.6%]) CVD 103-HgR recipients aged 2─5 years. Seroconversion in each of these age groups met prespecified non-inferiority criteria (lower limit of the 96.7% CIs on the difference between the groups exceeding -10) compared with adults 18─45 years from a phase III lot consistency study.
Loss to follow-up for SAEs (CVD 103-HgR 3/471 (0.6%), placebo 4/79 (5%)).
No SAEs were attributed to the vaccine in either study.
Very serious concern for imprecision based on the small sample size to assess rare serious adverse events, the small number of events, and the wide 95% confidence interval that crosses the line of no effect.
Loss to follow-up for solicited adverse events CVD 103-HgR: 3/471 (0.6%), placebo: 4/79 (5%).
Solicited adverse events were reported by a lower percentage of study participants aged 2–5 years (CVD 103-HgR: 40.4%, placebo: 34.6%) than aged 6–17 years (CVD 103-HgR: 61.8%, placebo: 59.2%). This may relate to limited language skills in the younger age group and was deemed not serious.
Serious concern for imprecision because the wide 95% confidence intervals cross the line of no effect.Table 5: Summary of evidence for outcomes of interest
Table 5: Summary of evidence for outcomes of interest
Outcome
Importance
Included in profile
CertaintyCholera diarrhea, moderate to severe
Critical
Yes
Type 2 (moderate)Cholera diarrhea, any severity
Critical
Yes
Type 2 (moderate)Serious adverse events
Critical
Yes
Type 3 (low)Non-serious adverse events
Important
Yes
Type 3 (low)Appendix 1: Studies Included in the Review of Evidence
Appendix 1: Studies included in the review of evidence
Last name first author, Publication year
Study design
Country (number of sites)
Age range, years
Total population
N
CVD 103-HgR
N
Placebo
Outcomes
Funding sourceMcCarty, 20204
Phase IV, randomized, double blind, placebo controlled
United States (7)
6–17
374
321
53
– Cholera diarrhea, any severity (assessed with immunobridging)
– Cholera diarrhea, any severity (assessed with immunobridging)
– Serious adverse events
– Other adverse events
CompanyMcCarty,
20203
Phase IV, randomized, double blind, placebo controlled
United States
(8 sites)
2–5
123
103
20
– Cholera diarrhea, any severity (assessed with immunobridging)
– Cholera diarrhea, any severity (assessed with immunobridging)
– Serious adverse events
– Other adverse events
CompanyMcCarty, 20215
Phase IV, randomized, double blind, placebo controlled
United States (4 sites)
12–17
95
72
23
– Cholera diarrhea, any severity (assessed with immunobridging)
– Cholera diarrhea, any severity (assessed with immunobridging)
CompanyAppendix 2. Search Strategies
Appendix 2. Search Strategies
Database
Search terms
Run Date
RecordsPubMed, Embase, Cochrane Library
cholera, *Vibrio cholerae,*CVD 103-HgR, cholera vaccine
6/16/2021
571Top of Page
							
					
							Last Reviewed:  August 25, 2022						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Vaccines & ImmunizationsImmunization SchedulesVFC ResolutionsVaccine Information Statements (VISs)
  1600 Clifton Road, N.E., Mailstop A27
Atlanta, GA 30329-4027acip@cdc.gov


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue